We are live on ! Find out more
NSPR icon

InspireMD

15 hedge funds and large institutions have $104K invested in InspireMD in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.79% less ownership

Funds ownership: 1.87%1.08% (-0.79%)

6% less funds holding

Funds holding: 1615 (-1)

24% less capital invested

Capital invested by funds: $137K → $104K (-$33K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change

NSPR Hedge Fund Activity: Q1 2023 in Review

15 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in InspireMD (NSPR) for Q1 2023, worth a combined $104K — down 24% from $137K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of NSPR and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 0 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $14.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $32.1K sold.

  • 15 institutional investors held InspireMD (NSPR) as of Q1 2023, down from 16 in Q4 2022.
  • Funds reported $104K of InspireMD stock for Q1 2023, down 24% quarter-over-quarter.
  • 2 funds opened new InspireMD positions in Q1 2023 and 3 closed out, a net change of -1 holder.
  • The largest InspireMD buyer in Q1 2023 was Millennium Management, an estimated $14.3K added.
  • The largest InspireMD seller in Q1 2023 was Citadel Advisors, an estimated $32.1K sold.

Based on aggregated 13F filings for Q1 2023.